The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its position within the broader sector now presents questions about long-term returns . Alternative versions are eroding exclusivity , leading to concerns that betting on companies significantly dependent to Viagra's former position could be a problematic